Key Points
- CFO Adam Laponis sold 3,000 shares on Jan. 13 at $40 each for $120,000, leaving him with 137,031 shares (a 2.14% reduction); he also sold 2,738 shares on Jan. 9 and 5,517 shares on Oct. 30, signaling ongoing insider selling.
- Twist opened at $41.27 with 50- and 200-day moving averages near $32.20 and $31.27, reported a quarterly EPS loss of $0.45 on $99.0M revenue and negative margins, while analysts hold a consensus “Moderate Buy” with an average price target of $44.67 after several firms raised targets.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 3,000 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $40.00, for a total transaction of $120,000.00. Following the transaction, the chief financial officer directly owned 137,031 shares of the company's stock, valued at $5,481,240. The trade was a 2.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Adam Laponis also recently made the following trade(s):
- On Friday, January 9th, Adam Laponis sold 2,738 shares of Twist Bioscience stock. The stock was sold at an average price of $35.26, for a total value of $96,541.88.
- On Thursday, October 30th, Adam Laponis sold 5,517 shares of Twist Bioscience stock. The stock was sold at an average price of $31.44, for a total value of $173,454.48.
Twist Bioscience Price Performance
TWST stock opened at $41.27 on Friday. The business's fifty day moving average price is $32.20 and its 200 day moving average price is $31.27. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $55.33. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $2.53 billion, a PE ratio of -31.50 and a beta of 2.19.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.05). The business had revenue of $99.01 million during the quarter, compared to analyst estimates of $97.40 million. Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. On average, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.
Analysts Set New Price Targets
TWST has been the topic of several research analyst reports. TD Cowen raised their target price on Twist Bioscience from $32.00 to $43.00 and gave the stock a "buy" rating in a research report on Thursday, January 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a report on Monday, December 29th. Stephens initiated coverage on shares of Twist Bioscience in a report on Monday, November 3rd. They issued an "overweight" rating and a $41.00 target price for the company. Evercore ISI reiterated an "outperform" rating and set a $42.00 price target on shares of Twist Bioscience in a research note on Monday, January 5th. Finally, Barclays boosted their price target on shares of Twist Bioscience from $37.00 to $39.00 and gave the company an "overweight" rating in a research report on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $44.67.
View Our Latest Stock Analysis on TWST
Hedge Funds Weigh In On Twist Bioscience
Hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock worth $85,000 after acquiring an additional 302 shares during the period. D.A. Davidson & CO. raised its holdings in Twist Bioscience by 1.5% during the second quarter. D.A. Davidson & CO. now owns 23,062 shares of the company's stock worth $848,000 after purchasing an additional 352 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company's stock valued at $29,000 after purchasing an additional 442 shares during the period. California State Teachers Retirement System boosted its holdings in Twist Bioscience by 0.8% in the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company's stock valued at $1,994,000 after purchasing an additional 442 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its position in Twist Bioscience by 8.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company's stock worth $222,000 after purchasing an additional 469 shares during the period.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
